Associating Mycobacterium tuberculosis genomic variants with minimum inhibitory concentrations to delamanid and pretomanid
Ana Tsutsunava, Nestani Tukvadze, Zaza Avaliani, Galo A Goig, Levan Jugheli, Sebastien Gagneux, Russell R Kempker, Nino Maghradze · 2026
Read Associating Mycobacterium tuberculosis genomic variants with minimum inhibitory concentrations to delamanid and pretomanid by Ana Tsutsunava, Nestani Tukvadze, Zaza Avaliani, Galo A Goig, Levan Jugheli, Sebastien Gagneux, Russell R Kempker, Nino Maghradze (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0359717.txt.
Description
Ana Tsutsunava and eight colleagues published this research article in PLOS ONE in 2026. It associates genomic variants of Mycobacterium tuberculosis, the TB bacterium, with minimum inhibitory concentrations for two newer TB drugs, delamanid and pretomanid. That concentration is the lowest drug level that stops the bacterium growing.
If gene patterns predict drug potency, laboratories could flag weak drug-bug matches from sequence alone, faster than growing cultures. Both drugs are vital for drug-resistant TB, where every effective medicine counts. TB reference labs and treatment programs are the readers for a genotype-to-potency link.
Catalog record
| CREATOR | Ana Tsutsunava, Nestani Tukvadze, Zaza Avaliani, Galo A Goig, Levan Jugheli, Sebastien Gagneux, Russell R Kempker, Nino Maghradze |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27753 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |